Renalytix PLC Notice of GM and Posting of Circular (0238Z)
11 May 2023 - 4:00PM
UK Regulatory
TIDMRENX
RNS Number : 0238Z
Renalytix PLC
11 May 2023
Renalytix plc
("Renalytix" or the "Company")
Notice of General Meeting and Posting of Circular
LONDON and SALT LAKE CITY, May 11, 2023 - Renalytix (NASDAQ:
RNLX) (LSE: RENX) announces that a circular containing a notice
convening a General Meeting to be held at the offices of Harwood
Capital LLP, 6 Stratton Street Mayfair, London W1J 8LD at 3 p.m.
(BST) on 8 June 2023, has today been posted to the Company's
shareholders.
An electronic copy of the circular will shortly be available on
the Company's website at www.renalytix.com in accordance with AIM
Rule 20.
For further information, please contact:
Renalytix plc www.renalytix.com
James McCullough, CEO Via Walbrook PR
Stifel (Nominated Adviser, Joint Broker) Tel: 020 7710 7600
Alex Price / Nicholas Moore / Nick Harland / Samira Essebiyea
Investec Bank plc (Joint Broker) Tel: 020 7597 4000
Gary Clarence / Shalin Bhamra
Walbrook PR Limited Tel: 020 7933 8780 or renalytix@walbrookpr.com
Paul McManus / Lianne Applegarth Mob: 07980 541 893 / 07584 391 303
CapComm Partners
Peter DeNardo Tel: 415-389-6400 or investors@renalytix.com
About Renalytix
Renalytix (NASDAQ: RNLX) (LSE: RENX) is an in-vitro diagnostics
and laboratory services company that is the global founder and
leader in the new field of bioprognosis(TM) for kidney health. The
leadership team, with a combined 200+ years of healthcare and
in-vitro diagnostic experience, has designed its KidneyIntelX
laboratory developed test to enable risk assessment for rapid
progressive decline in kidney function in adult patients with T2D
and early CKD (stages 1-3). We believe that by understanding how
disease will progress, patients and providers can take action early
to improve outcomes and reduce overall health system costs. For
more information, visit www.renalytix.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NOGEAFSEFEPDEAA
(END) Dow Jones Newswires
May 11, 2023 02:00 ET (06:00 GMT)
Renalytix (LSE:RENX)
Historical Stock Chart
From Apr 2024 to May 2024
Renalytix (LSE:RENX)
Historical Stock Chart
From May 2023 to May 2024